Tag: FGFR2

CD44 promotes angiogenesis in myocardial infarction through regulating plasma exosome uptake and further enhancing FGFR2 signaling transduction

Background: Since angiogenesis occurs as the pathological process following myocardial infarction to alleviate ischemia, therapeutic angiogenesis has been proposed to be a cardioprotective strategy. CD44 has been implicated in endothelial cell functions and its role has been well established in angiogenesis for years. Although recent studies indicate the close correlation…

Continue Reading CD44 promotes angiogenesis in myocardial infarction through regulating plasma exosome uptake and further enhancing FGFR2 signaling transduction

Derazantinib Shows Clinical Benefit, Manageable Safety Profile in Patients With Cholangiocarcinoma

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma. Treatment with derazantinib, an FGFR inhibitor, produced a meaningful clinical benefit with a manageable safety profile in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA), according to data from…

Continue Reading Derazantinib Shows Clinical Benefit, Manageable Safety Profile in Patients With Cholangiocarcinoma

Development of Combination Therapies for Biliary Tract Cancers: A Rational Approach

A rare group of gastrointestinal malignancies with a significant morbidity and death rate are biliary tract tumors. Most patients arrive with a locally progressed or metastatic illness that is incurable. It was possible to directly benefit from the pathophysiology of biliary tract cancer, and as a result, chemotherapy, precision medicine,…

Continue Reading Development of Combination Therapies for Biliary Tract Cancers: A Rational Approach

Cogent Biosciences to Showcase Precision Therapy Pipeline

WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR (“ENA”) annual meeting to be held October 26-28, 2022. Presentations…

Continue Reading Cogent Biosciences to Showcase Precision Therapy Pipeline

Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement. Pemigatinib (Pemazyre) showed a strong survival benefit in patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement, according to final…

Continue Reading Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma

Global Fibroblast Growth Factor Receptor 2 market key industry players and their market scope 2022

Pune, Maharashtra, India, September 22 2022 (Wiredrelease) Marke.biz–:The research provides the Global Fibroblast Growth Factor Receptor 2 Market aims at leveraging the insights and perspectives derived based on both qualitative and quantitative data evaluations for the forecast period, 2022-2030. The use of the technology for malady wipeout through direct correction of disturbances…

Continue Reading Global Fibroblast Growth Factor Receptor 2 market key industry players and their market scope 2022

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Official Trial Title A phase 3, open-label, randomized study of futibatinib versus germcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced cholagiocarcinoma harboring FGFR2 gene rearrangements (FOENIX-CCA3) Study Description The University of Virginia is participating in a global clinical research study for adults ages 18 years of age, and over…

Continue Reading A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

For This AI Drug Developer, Look Beyond the Rally

A handful of trendy biotech stocks in early August got swept up in meme-stock mania. Relay Therapeutics  (RLAY)  wasn’t one of them — but it still surged. The unheralded drug developer uses artificial intelligence, machine learning, and a supercomputer to design precision medicines.  The biotech stock saw daily trading volume of roughly…

Continue Reading For This AI Drug Developer, Look Beyond the Rally

MBD1/HDAC3-miR-5701-FGFR2 axis promotes the development of gastric cancer

Research Paper Advance Articles Changan Zhao1,2, *, , Jiyu Miao3, *, , Ruifang Sun1, *, , Rui Liang4, , Wenhu Chen5, , Yi Gao6, , Xiaofei Wang2, , Shuiping Han1, , Wenbao Zhao1, , Ting Lei1, , Chen Huang2,7, , 1 Department of Pathology, School of Basic Medical Sciences, Xi’an…

Continue Reading MBD1/HDAC3-miR-5701-FGFR2 axis promotes the development of gastric cancer

Diagnostics | Free Full-Text | The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer

Received: 10 May 2022 / Revised: 4 June 2022 / Accepted: 7 July 2022 / Published: 18 July 2022 Round 1 Reviewer 1 Report First of all, congratulations on your work. I would like to see a more elaborate and detailed conclusions chapter focusing on the clinical implications and how…

Continue Reading Diagnostics | Free Full-Text | The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer

The combined effects of Map3k1 mutation and dioxin on differentiation of keratinocytes derived from mouse embryonic stem cells

Byrne, C., Tainsky, M. & Fuchs, E. Programming gene expression in developing epidermis. Development 120, 2369–2383 (1994). CAS  PubMed  Article  Google Scholar  Pispa, J. & Thesleff, I. Mechanisms of ectodermal organogenesis. Dev. Biol. 262, 195–205 (2003). CAS  PubMed  Article  Google Scholar  Eckert, R. L., Crish, J. F. & Robinson, N….

Continue Reading The combined effects of Map3k1 mutation and dioxin on differentiation of keratinocytes derived from mouse embryonic stem cells

Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma

Background: Ameloblastoma imposes significant morbidity and high-recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined. Case: We describe a case of a 40-year-old male with multiply recurrent, locally invasive ameloblastoma of the posterior maxillary ridge. The tumor was…

Continue Reading Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma

Helsinn Expands US R&D Capabilities on Heels of BridgeBio Licensing Deal

Helsinn Group is expanding its global research and development capacity with the launch of a new dedicated hub in the U.S. The new R&D facility is a product of Helsinn’s new licensing deal with BridgeBio and will operate under Helsinn Therapeutics (U.S.). It will be instrumental in furthering the company’s projected increase in clinical activities to…

Continue Reading Helsinn Expands US R&D Capabilities on Heels of BridgeBio Licensing Deal

Variant #0000255165 (NC_000010.10:g.123278248A>G, FGFR2(NM_000141.4):c.939+1245T>C) – Global Variome shared LOVD

Variant #0000255165 (NC_000010.10:g.123278248A>G, FGFR2(NM_000141.4):c.939+1245T>C) Chromosome 10 Allele Unknown Affects function (as reported) Probably does not affect function Affects function (by curator) Not classified Classification method – Clinical classification likely benign DNA change (genomic) (Relative to hg19 / GRCh37) g.123278248A>G DNA change (hg38) g.121518734A>G Published as FGFR2(NM_022970.3):c.1035T>C (p.Y345=) ISCN – DB-ID FGFR2_000119 Variant remarks VKGL data sharing initiative Nederland Reference – ClinVar ID – dbSNP ID – Origin CLASSIFICATION record Segregation –…

Continue Reading Variant #0000255165 (NC_000010.10:g.123278248A>G, FGFR2(NM_000141.4):c.939+1245T>C) – Global Variome shared LOVD

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

Cogent Biosciences, Inc. Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class small molecule kinase inhibitors for genetically defined oncology indications and rare diseases Ended 1Q 2022 with $191.0 million in cash, sufficient…

Continue Reading Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

Dosing of KIN-3248 Begins in Advanced Solid Tumors With FGFR2 and/or FGFR3 Alterations

The first patient has been dosed in the phase 1 KN-4802 trial (NCT05242822) examining the safety, tolerability, and preliminary efficacy of KIN-3248, a next-generation pan-FGFR inhibitor, in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, according to a press release from Kinnate Biopharma Inc.1 KIN-3248 is an…

Continue Reading Dosing of KIN-3248 Begins in Advanced Solid Tumors With FGFR2 and/or FGFR3 Alterations

Cancer Discov: EGFR/FGFR dual target combination improves the clinical benefit of FGFR2 fusion cholangiocarcinoma

Treatment options for intrahepatic cholangiocarcinoma (ICC) are limited and the prognosis is usually poor after conventional chemotherapy. A variety of selective small-molecule FGFR1-3 kinase inhibitors are clinically effective, and the FDA has also approved the FGFR inhibitors pemigatinib and infigratinib for patients with ICC who have failed standard therapy and…

Continue Reading Cancer Discov: EGFR/FGFR dual target combination improves the clinical benefit of FGFR2 fusion cholangiocarcinoma

First Patient Treated in Study to Determine Tolerability, Dosing of Investigational Drug in Certain Solid Tumors

The first patient has received a dose of a novel drug candidate in an early-phase trial investigating the preliminary tolerability and proper dosage of the treatment in a group of patients with advanced solid tumors that harbor the FGFR2 and/or FGFR3 gene alterations, according to a press release. “With the…

Continue Reading First Patient Treated in Study to Determine Tolerability, Dosing of Investigational Drug in Certain Solid Tumors

FGFR2 antibody | Axil Scientific

This website uses cookies to ensure the best experience. By continuing, you agree to our privacy policy. × Product successfully added to quote! × There are items in your quote. Brand: Reference GTX10647 Brand GeneTex Application IHC-PWB Storage Conditions Store as concentrated solution. Centrifuge briefly prior to opening vial. For…

Continue Reading FGFR2 antibody | Axil Scientific

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma

FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined mechanisms. Here, we conducted high-throughput combination drug screens, biochemical analysis, and therapeutic studies using patient-derived models…

Continue Reading EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma

Your Source Of Daily World News Crypto Business Technology & Sports News

Cholangiocarcinoma, or bile duct most cancers, is lethal even when caught early. The 5-year survival rate amongst these identified early is 17% to 25%; for many sufferers, the speed is under 10%. Experts say the important thing to bettering these dismal statistics is to give attention to the various genetic…

Continue Reading Your Source Of Daily World News Crypto Business Technology & Sports News

Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome

W Reardon, R M Winter, P Rutland, L J Pulleyn, B M Jones, S Malcolm Nature Genetics 1994, 8 (1): 98-103 7987400 Crouzon syndrome is an autosomal dominant condition causing premature fusion of the cranial sutures (craniosynostosis) and maps to chromosome 10q25-q26. We now present evidence that mutations in the…

Continue Reading Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome

‘Majority of Patients’ With Cholangiocarcinoma Still Receive Upfront Standard of Care Despite Recent FDA Drug Approvals

Despite treatment advancements and Food and Drug Administration (FDA) approvals of drugs in the cholangiocarcinoma (a type of bile duct cancer) space in recent years, there are still many patients with this disease who are not eligible for targeted therapies as a first treatment option, highlighting a significant need for…

Continue Reading ‘Majority of Patients’ With Cholangiocarcinoma Still Receive Upfront Standard of Care Despite Recent FDA Drug Approvals

Pfeiffer syndrome with neonatal death secondary to tracheal obstruction owing to the FGFR2 Glu565Ala mutation.

Abstract We report a second patient with tracheal sleeve associated with an FGFR2 p.Glu565Ala mutation. This report describes a 30-week gestation male infant with Pfeiffer syndrome (PS) who died in the neonatal period with upper respiratory obstruction with three failed attempts at intubation before the onset of subcutaneous emphysema. The…

Continue Reading Pfeiffer syndrome with neonatal death secondary to tracheal obstruction owing to the FGFR2 Glu565Ala mutation.

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

Lugano, Switzerland and Palo Alto, CA – Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, announced an…

Continue Reading Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

DNMT1 is a negative regulator of osteogenesis

This article was originally published here Biol Open. 2022 Mar 15;11(3):bio058534. doi: 10.1242/bio.058534. Epub 2022 Mar 3. ABSTRACT The role and underlying mechanisms of DNA methylation in osteogenesis/chondrogenesis remain poorly understood. We here reveal DNA methyltransferase 1 (DNMT1), which is responsible for copying DNA methylation onto the newly synthesized DNA…

Continue Reading DNMT1 is a negative regulator of osteogenesis

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

Intrahepatic cholangiocarcinoma (iCCA) has emerged as a promising candidate for precision medicine, especially in the case of activating FGFR2 gene fusions. In addition to fusions, a considerable fraction of iCCA patients reveals FGFR2 mutations, which might lead to uncontrolled activation of the FGFR2 pathway but are mostly of unknown functional…

Continue Reading Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

Erdafitinib Yields Durable Responses in Advanced Urothelial Carcinoma

Erdafitinib demonstrated durable activity in patients with locally advanced or metastatic urothelial carcinoma with specific FGFR alterations, according to updated results from the BLC2001 trial published in The Lancet Oncology.1 The phase 2 BLC2001 trial (ClinicalTrials.gov Identifier: NCT02365597) was designed to investigate erdafitinib in patients with locally advanced and unresectable…

Continue Reading Erdafitinib Yields Durable Responses in Advanced Urothelial Carcinoma

FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells

Stem cell-based therapies offer significant potential for treating disease or injury through the regeneration of damaged tissues. Among the various stem cells available, mesenchymal stem cells (MSCs) are garnering considerable interest because of their availability, ease of isolation, and multipotency. Importantly, under appropriate culture conditions, MSCs can be selectively induced…

Continue Reading FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells

In Brief This Week: Innovent, Senhwa Biosciences, Oric Pharmaceuticals, Dizal Pharmaceutical

NEW YORK – Innovent this week said that pemigatinib (Pemazyre) was approved in Hong Kong as a treatment for locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. The approval was based on the Phase II FIGHT-202 study, which showed a 37 percent response rate for cholangiocarcinoma patients treated…

Continue Reading In Brief This Week: Innovent, Senhwa Biosciences, Oric Pharmaceuticals, Dizal Pharmaceutical

Basilea reports updated interim results for iCCA patients with FGFR2 mutations and

Basel, Switzerland, January 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that updated interim results from cohort 2 of the phase 2 study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors)…

Continue Reading Basilea reports updated interim results for iCCA patients with FGFR2 mutations and

FGFR2 signaling enhances the SHH-BMP4 signaling axis in early ureter development

The patterned array of basal, intermediate and superficial cells in the urothelium of the mature ureter arises from uncommitted epithelial progenitors of the distal ureteric bud. Urothelial development requires signaling input from surrounding mesenchymal cells, which, in turn, depend on cues from the epithelial primordium to form a layered fibro-muscular…

Continue Reading FGFR2 signaling enhances the SHH-BMP4 signaling axis in early ureter development

Basilea reports on portfolio progress made in 2021

Achieved important Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) milestones Added new clinical candidate BAL0891 to oncology pipeline and advanced clinical programs with derazantinib and lisavanbulin Basel, January 06, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases…

Continue Reading Basilea reports on portfolio progress made in 2021

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 andinitiates expansion cohorts in patients with FGFR2-altered solid tumors, including cholangiocarcinoma and breast cancer CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision…

Continue Reading Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

In Brief This Week: SkylineDx, TTC Oncology, LianBio

NEW YORK –  SkylineDx said this week that it has received a capital investment of undisclosed amount from US-based investment and advisory firm Novalis LifeSciences and from Netherlands-based Van Herk Investments. SkylineDx noted it is at a “critical growth stage,” with its first products introduced in the US. Its dermatology…

Continue Reading In Brief This Week: SkylineDx, TTC Oncology, LianBio

About: Pemigatinib

dbo:abstract Pemigatinib (INN), sold under the brand name Pemazyre, is a medication for the treatment of adults with previously treated, unresectable locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Pemigatinib works by…

Continue Reading About: Pemigatinib

10q26 FGFR2 Break Apart FISH Probe Kit

1 0q26 FGFR2 Break Apart FISH Probe Kit For Research Use Only Not for Use in Diagnostic Procedures 0q26 FGFR2 Break Apart FISH Probe Kit 09N /R2 Key to Symbols Used 09N /R2 Reference Number Lot Number Global Trade Item Number Centromere D0S294 0q26. Region FGFR2 5 ATE SHGC-529 Telomere…

Continue Reading 10q26 FGFR2 Break Apart FISH Probe Kit

The Evolving Treatment Landscape of Cholangiocarcinoma

Recent genomic profiling studies revealed that approximately 40% of patients with biliary tract cancers harbor actionable genomic mutations. The advances in the understanding and characterization of biliary tract cancers (BTCs), particularly intrahepatic cholangiocarcinoma (iCCA), and genomic profiling over the past decade have led to a rapid expansion of available treatment…

Continue Reading The Evolving Treatment Landscape of Cholangiocarcinoma

Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Continue Reading Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Predicting and characterizing a cancer dependency map of tumors with deep learning

INTRODUCTION The development of novel cancer therapies requires knowledge of specific biological pathways to target individual tumors and eradicate cancer cells. Toward this goal, the landscape of genetic vulnerabilities of cancer, or the cancer dependency map, is being systematically profiled. Using RNA interference (RNAi) loss-of-function screens, Marcotte et al. (1),…

Continue Reading Predicting and characterizing a cancer dependency map of tumors with deep learning

How to load Seurat Object into WGCNA Tutorial Format

As far as I can find, there is only one tutorial about loading Seurat objects into WGCNA (ucdavis-bioinformatics-training.github.io/2019-single-cell-RNA-sequencing-Workshop-UCD_UCSF/scrnaseq_analysis/scRNA_Workshop-PART6.html). I am really new to programming so it’s probably just my inexperience, but I am not sure how to load my Seurat object into a format that works with WGCNA’s tutorials (horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA/Tutorials/)….

Continue Reading How to load Seurat Object into WGCNA Tutorial Format